Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion
NASDAQ:RXST

RxSight Q3 2026 Earnings Date & Estimates

RxSight logo
$4.93 -0.09 (-1.79%)
Closing price 04:00 PM Eastern
Extended Trading
$4.93 0.00 (0.00%)
As of 06:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

RxSight is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from RxSight in Q3 2026

RxSight is expected to post earnings of -$0.29 per share on revenue of $27.19 million. In the same quarter a year earlier RxSight reported -$0.04 per share on revenue of $30.34 million. RxSight last reported on August 5, 2026, posting -$0.29 per share and beating the -$0.3294 consensus estimate. RxSight has beaten the consensus EPS estimate in 3 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.29
Expected Revenue
$27.19 million
Prior-Year EPS
-$0.04
Prior-Year Revenue
$30.34 million
Expected Revenue Growth
-10.4%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.29 (Beat by +$0.0394)
Last Quarter Revenue
$33.74 million
EPS Beat Rate
3 of last 8 quarters

Prepare for the Q3 2026 Call

RxSight Q3 2026 Earnings FAQ

RxSight (NASDAQ:RXST) is estimated to report Q3 2026 earnings on Tuesday, November 3, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

RxSight's Q3 2026 earnings conference call is scheduled for Tuesday, November 3, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect RxSight to post earnings of -$0.29 per share for Q3 2026.

The consensus revenue estimate for RxSight is $27.19 million for Q3 2026.

RxSight Earnings Headlines

RxSight (NASDAQ:RXST) Cut to Sell at Wall Street Zen
October 25 at 1:07 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31153805
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
October 23 at 8:00 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/24/3387637/0/en/rxsight-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules.html
My next big call (under $1)
17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community before the big move happened. Now, I'm making my next big call. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage. With Bitcoin well off its highs and fear still hanging over the market, this is the exact environment where my biggest winners have been found.tc pixel
October 26 at 1:00 AM  |  Crypto 101 Media (Ad)
RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3
October 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/20/3384940/0/en/rxsight-inc-to-report-third-quarter-2026-financial-results-on-november-3.html
RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation
October 19, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/rxsight-appoints-eye-care-industry-leaders-to-drive-commercial-transformation-1036638896
Analyzing Coloplast A/S (OTCMKTS:CLPBY) and RxSight (NASDAQ:RXST)
October 18, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31131258
See More RxSight Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like RxSight? Sign up for Earnings360's daily newsletter to receive timely earnings updates on RxSight and other key companies, straight to your email.

About RxSight

RxSight (NASDAQ:RXST) is a medical technology company focused on improving visual outcomes for patients undergoing cataract surgery. The company develops and commercializes ophthalmic products that allow surgeons to customize a patient’s vision after surgery.

Its primary product is the RxSight Light Adjustable Lens, an intraocular lens implanted during cataract surgery. After implantation, the lens can be adjusted using ultraviolet light treatments delivered by the company’s Light Delivery Device, enabling physicians to refine the lens power based on the patient’s postoperative visual needs. RxSight also offers related accessories, treatment planning tools and clinical support for the system.

Headquartered in Aliso Viejo, California, RxSight was previously known as Calhoun Vision before adopting its current name. The company’s Light Adjustable Lens technology received clearance from the U.S. Food and Drug Administration, and RxSight markets its products primarily through ophthalmic practices and surgical centers in the United States, with availability in select international markets.

View RxSight Profile
Earnings Tools